A double-blind, randomized, controlled crossover trial of glutamine supplementation in home parenteral nutritionCulkin, A., Gabe, S.M., Bjarnason, I., Grimble, G., Madden, A.M. and Forbes, A. (2008) A double-blind, randomized, controlled crossover trial of glutamine supplementation in home parenteral nutrition. European Journal of Clinical Nutrition, 62 (5). pp. 575-583. ISSN 0954-3007 Full text not archived in this repository. It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing. To link to this item DOI: 10.1038/sj.ejcn.1602754 Abstract/SummaryObjective: Studies suggest clinical benefit of glutamine-supplemented parenteral nutrition. The aim was to determine if the inclusion of 10 g of glutamine as part of the nitrogen source of home parenteral nutrition (HPN) reduces infectious complications. Subjects/Methods: Thirty-five patients on HPN were recruited and 22 completed the study. Patients were randomized to receive either standard HPN or glutamine-supplemented HPN. Patients were assessed at randomization, 3 and 6 months later then they were crossed over to the alternative HPN and reassessed at 3 and 6 months. Assessments included plasma amino acid concentrations, intestinal permeability and absorption, nutritional status, oral and parenteral intake, quality of life, routine biochemistry and haematology. Results: No difference was seen between the groups at randomization. No difference was detected between the treatment phases for infective complications (55% in the standard treatment phase and 36% in the glutamine-supplemented phase P 0.67). There were no differences in nutritional status, intestinal permeability, plasma glutamine concentrations or quality of life. Conclusion: Although limited by the sample size, the study has shown that glutamine as part of the nitrogen source of parenteral nutrition can be given to patients on HPN for 6 months without any adverse effects.
Altmetric Deposit Details University Staff: Request a correction | Centaur Editors: Update this record |